Marta Alonso-Varela1, Helena Gil-Peña2,3,4, Eliecer Coto1,5,6, Juan Gómez5,6, Julián Rodríguez1,7,5, Enrique Rodríguez-Rubio1, Fernando Santos1,7,5. 1. University of Oviedo, Oviedo, Spain. 2. University of Oviedo, Oviedo, Spain. hgilpena@gmail.com. 3. AGC de Pediatría, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain. hgilpena@gmail.com. 4. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. hgilpena@gmail.com. 5. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. 6. AGC Laboratorio - Genética, Hospital Universitario Central de Asturias, Oviedo, Spain. 7. AGC de Pediatría, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain.
Abstract
BACKGROUND: To evaluate whether there are differences in the phenotype of primary distal renal tubular acidosis (dRTA) patients according to the causal defective gene. METHODS: Twenty-seven non-oriental patients with genetically confirmed dRTA were grouped according to the identified underlying mutations in either ATP6V1B1 (n = 10), ATP6V0A4 (n = 12), or SLC4A1 (n = 5) gene. Demographic features, growth impairment, biochemical variables and presence of deafness, nephrocalcinosis, and urolithiasis at diagnosis were compared among the three groups. RESULTS: Patients with SLC4A1 mutations presented later than those with ATP6V1B1 or ATP6V0A4 defects (120 vs. 7 and 3 months, respectively). Hearing loss at diagnosis was present in the majority of patients with ATP6V1B1 mutations, in two patients with ATP6V0A4 mutations, and in none of cases harboring SLC4A1 mutations. Serum potassium concentration (X ± SD) was higher in SLC4A1 group (3.66 ± 0.44 mEq/L) than in ATP6V0A4 group (2.96 ± 0.63 mEq/L) (p = 0.046). There were no differences in the other clinical or biochemical variables analyzed in the three groups. CONCLUSIONS: This study indicates that non-oriental patients with dRTA caused by mutations in the SLC4A1 gene present later and have normokalemia or milder hypokalemia. Hypoacusia at diagnosis is characteristically associated with ATP6V1B1 gene mutations although it may also be present in infants with ATP6V0A4 defects. Other phenotypical manifestations do not allow predicting the involved gene.
BACKGROUND: To evaluate whether there are differences in the phenotype of primary distal renal tubular acidosis (dRTA) patients according to the causal defective gene. METHODS: Twenty-seven non-oriental patients with genetically confirmed dRTA were grouped according to the identified underlying mutations in either ATP6V1B1 (n = 10), ATP6V0A4 (n = 12), or SLC4A1 (n = 5) gene. Demographic features, growth impairment, biochemical variables and presence of deafness, nephrocalcinosis, and urolithiasis at diagnosis were compared among the three groups. RESULTS:Patients with SLC4A1 mutations presented later than those with ATP6V1B1 or ATP6V0A4 defects (120 vs. 7 and 3 months, respectively). Hearing loss at diagnosis was present in the majority of patients with ATP6V1B1 mutations, in two patients with ATP6V0A4 mutations, and in none of cases harboring SLC4A1 mutations. Serum potassium concentration (X ± SD) was higher in SLC4A1 group (3.66 ± 0.44 mEq/L) than in ATP6V0A4 group (2.96 ± 0.63 mEq/L) (p = 0.046). There were no differences in the other clinical or biochemical variables analyzed in the three groups. CONCLUSIONS: This study indicates that non-oriental patients with dRTA caused by mutations in the SLC4A1 gene present later and have normokalemia or milder hypokalemia. Hypoacusia at diagnosis is characteristically associated with ATP6V1B1 gene mutations although it may also be present in infants with ATP6V0A4 defects. Other phenotypical manifestations do not allow predicting the involved gene.
Authors: P Jarolim; C Shayakul; D Prabakaran; L Jiang; A Stuart-Tilley; H L Rubin; S Simova; J Zavadil; J T Herrin; J Brouillette; M J Somers; E Seemanova; C Brugnara; L M Guay-Woodford; S L Alper Journal: J Biol Chem Date: 1998-03-13 Impact factor: 5.157
Authors: E H Stover; K J Borthwick; C Bavalia; N Eady; D M Fritz; N Rungroj; A B S Giersch; C C Morton; P R Axon; I Akil; E A Al-Sabban; D M Baguley; S Bianca; A Bakkaloglu; Z Bircan; D Chauveau; M-J Clermont; A Guala; S A Hulton; H Kroes; G Li Volti; S Mir; H Mocan; A Nayir; S Ozen; J Rodriguez Soriano; S A Sanjad; V Tasic; C M Taylor; R Topaloglu; A N Smith; F E Karet Journal: J Med Genet Date: 2002-11 Impact factor: 6.318
Authors: N Mohebbi; R Vargas-Poussou; S C A Hegemann; B Schuknecht; A D Kistler; R P Wüthrich; C A Wagner Journal: Clin Genet Date: 2012-05-11 Impact factor: 4.438
Authors: A N Smith; J Skaug; K A Choate; A Nayir; A Bakkaloglu; S Ozen; S A Hulton; S A Sanjad; E A Al-Sabban; R P Lifton; S W Scherer; F E Karet Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: V S Tanphaichitr; A Sumboonnanonda; H Ideguchi; C Shayakul; C Brugnara; M Takao; G Veerakul; S L Alper Journal: J Clin Invest Date: 1998-12-15 Impact factor: 14.808
Authors: Laura I Escobar; Christopher Simian; Cyrielle Treard; Donia Hayek; Carolina Salvador; Norma Guerra; Mario Matos; Mara Medeiros; Sandra Enciso; María Dolores Camargo; Rosa Vargas-Poussou Journal: Mol Genet Genomic Med Date: 2016-02-14 Impact factor: 2.183
Authors: Jessica M Forero-Delgadillo; Helena Gil-Peña; Marta Alonso-Varela; Fernando Santos Journal: Pediatr Nephrol Date: 2021-04-08 Impact factor: 3.714